Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Portola Pharmaceuticals Inc's Business Segments
Portola Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 26
Regions Reported
-
Portola Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product97.2%
- License and Service2.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 26 | 97.2% |
| License and Service | $ 1 | 2.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Portola Pharmaceuticals Inc
Portola Pharmaceuticals Inc. is a biotechnology company headquartered in South San Francisco, California. The company is focused on developing and commercializing novel therapeutics for the treatment of life-threatening thrombosis and hematologic disorders. The company was founded in January 2003 and has been publicly traded on the NASDAQ stock exchange since 200
Portola’s proprietary pipeline includes four investigational drugs in various stages of development. Betrixaban is an oral, once-daily Factor Xa inhibitor that is being investigated for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Cerdulatinib is a dual Syk/JAK kinase inhibitor being investigated for hematologic cancers such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Andexanet alfa is an anticoagulant reversal agent being developed to reverse the anticoagulant effects of Factor Xa inhibitors like betrixaban and apixaban. Syk inhibitor is part of the company's preclinical pipeline, which is being evaluated as a treatment for various autoimmune disorders.
In 2015, Portola received its first FDA approval for Bevyxxa (betrixaban). It is the first and only FDA-approved oral anticoagulant for the extended prevention of VTE in acute medically ill patients. In 2018, the company received its second FDA approval for Andexxa for the reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding.
Portola has partnerships with major pharmaceutical companies such as Pfizer, Bristol-Myers Squibb and Alexion Pharmaceuticals to further develop and commercialize its pipeline products. The company has a team of experienced scientists, researchers, and business professionals who are committed to discovering innovative treatments to improve patient outcomes worldwide.
Portola's core values include innovation, collaboration, integrity, respect, and excellence, which it believes are key to driving its efforts to develop transformative medicines that help save patients' lives. The company is dedicated to investing in science and technology to advance the fields of thrombosis and hematology, working to develop new solutions that can address unmet patient needs.
Portola’s proprietary pipeline includes four investigational drugs in various stages of development. Betrixaban is an oral, once-daily Factor Xa inhibitor that is being investigated for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Cerdulatinib is a dual Syk/JAK kinase inhibitor being investigated for hematologic cancers such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Andexanet alfa is an anticoagulant reversal agent being developed to reverse the anticoagulant effects of Factor Xa inhibitors like betrixaban and apixaban. Syk inhibitor is part of the company's preclinical pipeline, which is being evaluated as a treatment for various autoimmune disorders.
In 2015, Portola received its first FDA approval for Bevyxxa (betrixaban). It is the first and only FDA-approved oral anticoagulant for the extended prevention of VTE in acute medically ill patients. In 2018, the company received its second FDA approval for Andexxa for the reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding.
Portola has partnerships with major pharmaceutical companies such as Pfizer, Bristol-Myers Squibb and Alexion Pharmaceuticals to further develop and commercialize its pipeline products. The company has a team of experienced scientists, researchers, and business professionals who are committed to discovering innovative treatments to improve patient outcomes worldwide.
Portola's core values include innovation, collaboration, integrity, respect, and excellence, which it believes are key to driving its efforts to develop transformative medicines that help save patients' lives. The company is dedicated to investing in science and technology to advance the fields of thrombosis and hematology, working to develop new solutions that can address unmet patient needs.
Portola Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies that address significant unmet medical needs, particularly within the realms of bleeding disorders and various malignancies. The company operates through two primary segments—Commercial Operations and Research and Development—and offers a diverse portfolio of products and services aimed at enhancing patient outcomes.
Segments:
1. Commercial Operations:
This segment focuses on the marketing, sales, and distribution of Portolas approved therapies. The company currently has two FDA-approved drugs:
- Andexxa (coagulation factor Xa recombinant, inactivated-zhzo): This is the first and only FDA-approved antidote for individuals treated with rivaroxaban (Xarelto) and apixaban (Eliquis). It effectively reverses the anticoagulant effects of these medications in emergency situations, significantly reducing the risk of bleeding complications in patients who may be experiencing severe bleeding events.
- Bevyxxa (betrixaban): This oral anticoagulant is prescribed for extended thromboprophylaxis in hospitalized adult patients. Bevyxxa provides once-daily dosing, which contributes to medication adherence and simplifies management for healthcare providers. Its unique pharmacokinetic profile allows for predictable anticoagulation, making it an important option for preventing venous thromboembolism in at-risk patients.
Portola is actively engaged in expanding the reach of these products, improving their adoption rates among healthcare providers, and exploring additional indications where these therapies may provide clinical benefits.
Research and Development:
The R&D segment is at the forefront of Portola’s growth strategy, focused on pipeline advancements and the introduction of new therapies. The company is investigating several novel compounds across various clinical indications:
- Cerdulatinib: This dual Syk-JAK inhibitor is in development for treating hematologic malignancies as well as autoimmune diseases. Its unique mechanism of action may provide new treatment avenues for patients suffering from these challenging conditions.
- Factor XIa Inhibitor: An oral, selective inhibitor that targets factor XIa, this compound shows promise for delivering effective anticoagulation while minimizing the associated bleeding risks—particularly relevant in procedures like percutaneous coronary intervention (PCI).
- Fonduparinux: Serving as a synthetic alternative to traditional heparin, Fonduparinux is being studied for indications such as acute coronary syndrome (ACS) and deep vein thrombosis (DVT). By offering a potentially safer anticoagulation option, this drug could improve patient outcomes in various clinical settings.
Products:
1. Andexxa:
- Mechanism: It works by binding to factor Xa inhibitors, effectively neutralizing their anticoagulant effects and allowing for rapid restoration of normal blood clotting mechanisms.
- Administration: Delivered via intravenous infusion, Andexxa is crucial in emergency care settings where rapid reversal of anticoagulation is necessitated, such as in trauma cases or surgical emergencies.
2. Bevyxxa:
- Mechanism: As a long-acting oral anticoagulant, Bevyxxa targets factor Xa to prevent thrombus formation, particularly in hospitalized patients at risk for thromboembolic events.
- Administration: It is offered in a single daily tablet form, enhancing patient convenience and compliance, essential in hospital settings where the risk for thrombosis is elevated.
Services:
1. Medical Education and Training:
- Portola actively engages healthcare professionals through educational initiatives, ensuring they remain well-informed regarding the pharmacological profiles of its products, optimal patient management techniques, and the latest clinical data supporting the use of its therapies. This is crucial for improving prescribing practices and enhancing patient care.
2. Patient Support Services:
- Understanding the challenges faced by patients, Portola provides robust support resources, including:
- Financial Assistance: Programs designed to alleviate the financial burden of treatment for eligible patients who may struggle with costs.
- Nursing Support: Access to specialized nursing staff who guide patients on managing their conditions and assist with treatment adherence.
- Disease Management Information: Educational resources aimed at empowering patients by informing them about their conditions and available treatment options.
3. Clinical Trials:
- Portola Pharmaceuticals is dedicated to advancing medical science by conducting rigorous clinical trials that investigate the safety and efficacy of new compounds. These trials are a collaborative effort with leading medical institutions globally and encompass various demographics and conditions. The commitment to ethical conduct and patient safety remains a cornerstone of their research activities.
In summary, Portola Pharmaceuticals is firmly positioned as an innovative leader in the biopharmaceutical field, providing essential therapies and comprehensive support services that cater to patients with serious health conditions. With a strong commitment to research and excellence in patient care, Portola is dedicated to addressing the challenges faced in the treatment of bleeding disorders and beyond.
Segments:
1. Commercial Operations:
This segment focuses on the marketing, sales, and distribution of Portolas approved therapies. The company currently has two FDA-approved drugs:
- Andexxa (coagulation factor Xa recombinant, inactivated-zhzo): This is the first and only FDA-approved antidote for individuals treated with rivaroxaban (Xarelto) and apixaban (Eliquis). It effectively reverses the anticoagulant effects of these medications in emergency situations, significantly reducing the risk of bleeding complications in patients who may be experiencing severe bleeding events.
- Bevyxxa (betrixaban): This oral anticoagulant is prescribed for extended thromboprophylaxis in hospitalized adult patients. Bevyxxa provides once-daily dosing, which contributes to medication adherence and simplifies management for healthcare providers. Its unique pharmacokinetic profile allows for predictable anticoagulation, making it an important option for preventing venous thromboembolism in at-risk patients.
Portola is actively engaged in expanding the reach of these products, improving their adoption rates among healthcare providers, and exploring additional indications where these therapies may provide clinical benefits.
Research and Development:
The R&D segment is at the forefront of Portola’s growth strategy, focused on pipeline advancements and the introduction of new therapies. The company is investigating several novel compounds across various clinical indications:
- Cerdulatinib: This dual Syk-JAK inhibitor is in development for treating hematologic malignancies as well as autoimmune diseases. Its unique mechanism of action may provide new treatment avenues for patients suffering from these challenging conditions.
- Factor XIa Inhibitor: An oral, selective inhibitor that targets factor XIa, this compound shows promise for delivering effective anticoagulation while minimizing the associated bleeding risks—particularly relevant in procedures like percutaneous coronary intervention (PCI).
- Fonduparinux: Serving as a synthetic alternative to traditional heparin, Fonduparinux is being studied for indications such as acute coronary syndrome (ACS) and deep vein thrombosis (DVT). By offering a potentially safer anticoagulation option, this drug could improve patient outcomes in various clinical settings.
Products:
1. Andexxa:
- Mechanism: It works by binding to factor Xa inhibitors, effectively neutralizing their anticoagulant effects and allowing for rapid restoration of normal blood clotting mechanisms.
- Administration: Delivered via intravenous infusion, Andexxa is crucial in emergency care settings where rapid reversal of anticoagulation is necessitated, such as in trauma cases or surgical emergencies.
2. Bevyxxa:
- Mechanism: As a long-acting oral anticoagulant, Bevyxxa targets factor Xa to prevent thrombus formation, particularly in hospitalized patients at risk for thromboembolic events.
- Administration: It is offered in a single daily tablet form, enhancing patient convenience and compliance, essential in hospital settings where the risk for thrombosis is elevated.
Services:
1. Medical Education and Training:
- Portola actively engages healthcare professionals through educational initiatives, ensuring they remain well-informed regarding the pharmacological profiles of its products, optimal patient management techniques, and the latest clinical data supporting the use of its therapies. This is crucial for improving prescribing practices and enhancing patient care.
2. Patient Support Services:
- Understanding the challenges faced by patients, Portola provides robust support resources, including:
- Financial Assistance: Programs designed to alleviate the financial burden of treatment for eligible patients who may struggle with costs.
- Nursing Support: Access to specialized nursing staff who guide patients on managing their conditions and assist with treatment adherence.
- Disease Management Information: Educational resources aimed at empowering patients by informing them about their conditions and available treatment options.
3. Clinical Trials:
- Portola Pharmaceuticals is dedicated to advancing medical science by conducting rigorous clinical trials that investigate the safety and efficacy of new compounds. These trials are a collaborative effort with leading medical institutions globally and encompass various demographics and conditions. The commitment to ethical conduct and patient safety remains a cornerstone of their research activities.
In summary, Portola Pharmaceuticals is firmly positioned as an innovative leader in the biopharmaceutical field, providing essential therapies and comprehensive support services that cater to patients with serious health conditions. With a strong commitment to research and excellence in patient care, Portola is dedicated to addressing the challenges faced in the treatment of bleeding disorders and beyond.